Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA Source: Eur Respir J 2012; 39: 1261-1263 Year: 2012
Weekly nebulisation of liposomal amphotericin B for the treatment of endobronchial aspergillus fumigatus infection in cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 213s Year: 2004
Clinical efficacy and safety of micafungin in patients with pulmonary aspergillosis Source: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006
Efficacy and tolerability of voriconazole in the treatment of pulmonary aspergillosis Source: Eur Respir J 2007; 30: Suppl. 51, 301s Year: 2007
The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017
In vitro lung deposition evaluation of liposomal Amphotericin B with 6 different nebulizer systemsSource: Eur Respir J 2002; 20: Suppl. 38, 16s Year: 2002
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Source: Eur Respir J 2008; 31: 908-909 Year: 2008
Treatment of chronic pulmonary aspergillosis by voriconazole compared with micafungin Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus Year: 2009
Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003
Pulmonary aspergillosis during pregnancy: tolerability and safety of terbinafine Source: Eur Respir J 2002; 20: Suppl. 38, 352s Year: 2002
Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
An open label randomized controlled trial comparing nebulized amphotericin B with oral itraconazole in patients with pulmonary aspergilloma Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies Source: Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020 Year: 2020
Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013
Effects of PC945, a novel antifungal agent optimised for lung delivery, on Candida albicans lung infection in mice Source: Virtual Congress 2020 – Translational science in respiratory infections Year: 2020